EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

Dose modulation strategies in patients with psoriasis: real-world comparison between secukinumab and brodalumab for up to 1 year after dose spacing

Luca Mastorino, Paolo Dapavo, Michela Ortoncelli, Eleonora Bongiovanni iD, Yingying Liao, Margherita Pelucchi, Francesco Leo, Pietro Quaglino, Simone Ribero

Clinical and Experimental Dermatology · 2025

DOI: 10.1093/ced/llaf250 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Clinical and Experimental Dermatology, 2025. Verfasst von Luca Mastorino und 8 weiteren Autor:innen. Beteiligte Einrichtung: Dermatology Clinic, Department of Medical Sciences, University of Turin, Turin, Italy. Hauptthemen laut MEDLINE: Psoriasis, Antibodies, Monoclonal, Humanized, Dermatologic Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Modulating the regimen of biologics is of increasing interest in patients with psoriasis. This includes dose reduction (de-escalation) and dose augmentation (escalation). De-escalation strategies include reducing the single therapeutic dose, the mg kg−1 ratio or the number of injections, and dose spacing (D-S), extending the interval between administrations. Real-life data regarding dose de-escalation are lacking.

Objectives

To retrospectively analyse the effectiveness and drug survival of D-S of secukinumab and brodalumab in a real-world setting.

Methods

This is a cohort study with retrospective analysis of the general characteristics of patients with psoriasis undergoing therapeutic biologic D-S with secukinumab or brodalumab and the effectiveness of D-S.

Results

Eighty patients underwent dose modulation by D-S with the interval increased by 50% of the approved range. Overall, 31 (39%) were treated with secukinumab and 49 (61%) with brodalumab. After a mean of 35 months, the population underwent D-S. At D-S, the mean Psoriasis Area and Severity Index (PASI) was 0.1, ranging from 0.7 to 0.1 in the following year. PASI 100 (100% improvement) was achieved by 91% at the date of D-S and remained stable over the following year. Similar trends were seen for PASI 90 and absolute PASI ≤ 1, with 99% and 100% of patients, respectively, achieving these goals at the time of D-S. These levels were maintained at 12 months after D-S. The 12-month drug survival of the D-S regimen was 66%, with one-quarter of patients (20 of 80) returning to the standard dosage. PASI 100 was regained in two-thirds of these cases. Secukinumab showed a drug survival after D-S of 78%, compared with 59% for brodalumab. No differences in mean and relative PASI scores at any timepoint after D-S were found between the two treatments.

Conclusions

Therapeutic modulation of interleukin-17 inhibitors in patients with psoriasis and controlled disease seems an effective therapeutic strategy that maintains efficacy for up to 1 year in 40% of patients. No differences were observed between secukinumab and brodalumab during the D-S regimen.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PsoriasisAntibodies, Monoclonal, HumanizedDermatologic AgentsHumansMaleFemaleRetrospective StudiesMiddle AgedAdultTreatment OutcomeAgedDrug Administration ScheduleDose-Response Relationship, Drug

Substanzen

secukinumabAntibodies, Monoclonal, HumanizedbrodalumabDermatologic Agents

Autor:innen und Institutionen

  • Dermatology Clinic, Department of Medical Sciences, University of Turin, Turin, Italy.

ORCID-Profile: Eleonora Bongiovanni

Zitieren

APA

Mastorino, L., Dapavo, P., Ortoncelli, M., Bongiovanni, E., Liao, Y., Pelucchi, M., Leo, F., Quaglino, P., & Ribero, S. (2025). Dose modulation strategies in patients with psoriasis: real-world comparison between secukinumab and brodalumab for up to 1 year after dose spacing. Clinical and Experimental Dermatology. https://doi.org/10.1093/ced/llaf250

Vancouver

Mastorino L, Dapavo P, Ortoncelli M, Bongiovanni E, Liao Y, Pelucchi M, et al. Dose modulation strategies in patients with psoriasis: real-world comparison between secukinumab and brodalumab for up to 1 year after dose spacing. Clinical and Experimental Dermatology. 2025. doi:10.1093/ced/llaf250

BibTeX
@article{Mastorino2025,
  author = {Mastorino, Luca and Dapavo, Paolo and Ortoncelli, Michela and Bongiovanni, Eleonora and Liao, Yingying and Pelucchi, Margherita and Leo, Francesco and Quaglino, Pietro and Ribero, Simone},
  title = {Dose modulation strategies in patients with psoriasis: real-world comparison between secukinumab and brodalumab for up to 1 year after dose spacing},
  journal = {Clinical and Experimental Dermatology},
  year = {2025},
  doi = {10.1093/ced/llaf250}
}
Kostenlos starten →